These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 34046181)

  • 1. Development of a cobalt(iii)-based ponatinib prodrug system.
    Mathuber M; Gutmann M; La Franca M; Vician P; Laemmerer A; Moser P; Keppler BK; Berger W; Kowol CR
    Inorg Chem Front; 2021 Mar; 8(10):2468-2485. PubMed ID: 34046181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improving the Stability of EGFR Inhibitor Cobalt(III) Prodrugs.
    Mathuber M; Schueffl H; Dömötör O; Karnthaler C; Enyedy ÉA; Heffeter P; Keppler BK; Kowol CR
    Inorg Chem; 2020 Dec; 59(23):17794-17810. PubMed ID: 33222438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.
    Gozgit JM; Wong MJ; Moran L; Wardwell S; Mohemmad QK; Narasimhan NI; Shakespeare WC; Wang F; Clackson T; Rivera VM
    Mol Cancer Ther; 2012 Mar; 11(3):690-9. PubMed ID: 22238366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel EGFR inhibitor acts as potent tool for hypoxia-activated prodrug systems and exerts strong synergistic activity with VEGFR inhibition in vitro and in vivo.
    Caban M; Koblmueller B; Groza D; Schueffl HH; Terenzi A; Tolios A; Mohr T; Mathuber M; Kryeziu K; Jaunecker C; Pirker C; Keppler BK; Berger W; Kowol CR; Heffeter P
    Cancer Lett; 2023 Jul; 565():216237. PubMed ID: 37211067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How does the novel T315L mutation of breakpoint cluster region-abelson (BCR-ABL) kinase confer resistance to ponatinib: a comparative molecular dynamics simulation study.
    Zhang H; He X; Ni D; Mou L; Chen X; Lu S
    J Biomol Struct Dyn; 2020 Jan; 38(1):89-100. PubMed ID: 30661457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combining the ABL1 kinase inhibitor ponatinib and the histone deacetylase inhibitor vorinostat: a potential treatment for BCR-ABL-positive leukemia.
    Okabe S; Tauchi T; Kimura S; Maekawa T; Kitahara T; Tanaka Y; Ohyashiki K
    PLoS One; 2014; 9(2):e89080. PubMed ID: 24586514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies.
    Gozgit JM; Wong MJ; Wardwell S; Tyner JW; Loriaux MM; Mohemmad QK; Narasimhan NI; Shakespeare WC; Wang F; Druker BJ; Clackson T; Rivera VM
    Mol Cancer Ther; 2011 Jun; 10(6):1028-35. PubMed ID: 21482694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of panobinostat with ponatinib synergistically overcomes imatinib-resistant CML cells.
    Matsuda Y; Yamauchi T; Hosono N; Uzui K; Negoro E; Morinaga K; Nishi R; Yoshida A; Kimura S; Maekawa T; Ueda T
    Cancer Sci; 2016 Jul; 107(7):1029-38. PubMed ID: 27166836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and biological investigations of hypoxia-sensitive prodrugs of the tyrosine kinase inhibitor crizotinib.
    Bielec B; Schueffl H; Terenzi A; Berger W; Heffeter P; Keppler BK; Kowol CR
    Bioorg Chem; 2020 Jun; 99():103778. PubMed ID: 32229347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PF-114, a potent and selective inhibitor of native and mutated BCR/ABL is active against Philadelphia chromosome-positive (Ph+) leukemias harboring the T315I mutation.
    Mian AA; Rafiei A; Haberbosch I; Zeifman A; Titov I; Stroylov V; Metodieva A; Stroganov O; Novikov F; Brill B; Chilov G; Hoelzer D; Ottmann OG; Ruthardt M
    Leukemia; 2015 May; 29(5):1104-14. PubMed ID: 25394714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipid droplet-mediated scavenging as novel intrinsic and adaptive resistance factor against the multikinase inhibitor ponatinib.
    Englinger B; Laemmerer A; Moser P; Kallus S; Röhrl C; Pirker C; Baier D; Mohr T; Niederstaetter L; Meier-Menches SM; Gerner C; Gabler L; Gojo J; Timelthaler G; Senkiv J; Jäger W; Kowol CR; Heffeter P; Berger W
    Int J Cancer; 2020 Sep; 147(6):1680-1693. PubMed ID: 32064608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive models for designing potent tyrosine kinase inhibitors in chronic myeloid leukemia for understanding its molecular mechanism of resistance by molecular docking and dynamics simulations.
    Melge AR; Kumar LG; K P; Nair SV; K M; C GM
    J Biomol Struct Dyn; 2019 Nov; 37(18):4747-4766. PubMed ID: 30580670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor-Sensitive and -Resistant Chronic Myeloid Leukemia.
    Ben-Batalla I; Erdmann R; Jørgensen H; Mitchell R; Ernst T; von Amsberg G; Schafhausen P; Velthaus JL; Rankin S; Clark RE; Koschmieder S; Schultze A; Mitra S; Vandenberghe P; Brümmendorf TH; Carmeliet P; Hochhaus A; Pantel K; Bokemeyer C; Helgason GV; Holyoake TL; Loges S
    Clin Cancer Res; 2017 May; 23(9):2289-2300. PubMed ID: 27856601
    [No Abstract]   [Full Text] [Related]  

  • 14. Design, synthesis, and biological evaluations of novel 3-amino-4-ethynyl indazole derivatives as Bcr-Abl kinase inhibitors with potent cellular antileukemic activity.
    El-Damasy AK; Jin H; Seo SH; Bang EK; Keum G
    Eur J Med Chem; 2020 Dec; 207():112710. PubMed ID: 32961435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Shamroe CL; Comeau JM
    Ann Pharmacother; 2013 Nov; 47(11):1540-6. PubMed ID: 24265264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ponatinib: a novel multi-tyrosine kinase inhibitor against human malignancies.
    Tan FH; Putoczki TL; Stylli SS; Luwor RB
    Onco Targets Ther; 2019; 12():635-645. PubMed ID: 30705592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of ponatinib in vitro effect in three canine mast cell tumor cell lines expressing FGFR-1, PDGFR-α, and VEGFR-2.
    Fisher CJ; Lejeune AT; Dark MJ; Hernandez OM; Shiomitsu K
    Vet J; 2021 Mar; 269():105621. PubMed ID: 33593493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hitting two oncogenic machineries in cancer cells: cooperative effects of the multi-kinase inhibitor ponatinib and the BET bromodomain blockers JQ1 or dBET1 on human carcinoma cells.
    Bauer K; Berger D; Zielinski CC; Valent P; Grunt TW
    Oncotarget; 2018 May; 9(41):26491-26506. PubMed ID: 29899872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.
    Redaelli S; Mologni L; Rostagno R; Piazza R; Magistroni V; Ceccon M; Viltadi M; Flynn D; Gambacorti-Passerini C
    Am J Hematol; 2012 Nov; 87(11):E125-8. PubMed ID: 23044928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of ponatinib with Hedgehog antagonist vismodegib for therapy-resistant BCR-ABL1-positive leukemia.
    Katagiri S; Tauchi T; Okabe S; Minami Y; Kimura S; Maekawa T; Naoe T; Ohyashiki K
    Clin Cancer Res; 2013 Mar; 19(6):1422-32. PubMed ID: 23319824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.